StockData
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30
$9.13+0.57 (+6.66%)

Close on Nov 19, 2026Market cap $815.28MP/E –Yield –

Syndax Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Syndax Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2018 was -$68.72M. For fiscal 2025 it was -$323.17M. The highest annual figure on record is $29.00M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$323.17M–
FY2024Dec 31, 2024-$274.90M–
FY2023Dec 31, 2023-$160.60M–
FY2022Dec 31, 2022-$133.68M-560.9%
FY2021Dec 31, 2021$29.00M–
FY2020Dec 31, 2020-$71.26M–
FY2018Dec 31, 2018-$68.72M–
FY2017Dec 31, 2017-$47.46M–
FY2016Dec 31, 2016-$35.42M–
FY2015Dec 31, 2015-$2.48M–
FY2014Dec 31, 2014-$14.40M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2018Dec 31, 2018-$15.06M–
Q3 FY2018Sep 30, 2018-$18.47M–
Q2 FY2018Jun 30, 2018-$15.15M–
Q1 FY2018Mar 31, 2018-$20.04M–
Q4 FY2017Dec 31, 2017-$12.76M–
Q4 FY2016Dec 31, 2016-$10.42M–

More Syndax Pharmaceuticals figures

See a number that looks wrong?